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Genetic studies of human diseases have identified multiple genetic risk loci for various
fibrotic diseases. This has provided insights into the myriad of biological pathways
potentially involved in disease pathogenesis. These discoveries suggest that alterations
in immune responses, barrier function, metabolism and telomerase activity may be
implicated in the genetic risks for fibrotic diseases. In addition to genetic disease-risks, the
identification of genetic disease-modifiers associated with disease complications, severity
or prognosis provides crucial insights into the biological processes implicated in disease
progression. Understanding the biological processes driving disease progression may be
critical to delineate more effective strategies for therapeutic interventions. This review
provides an overview of current knowledge and gaps regarding genetic disease-risks and
genetic disease-modifiers in human fibrotic diseases.
Keywords: fibrosis, auto-immunity, genetics, GWAS, disease progression
INTRODUCTION
Fibrosis arises as the result of excessive connective tissue and
extracellular matrix deposition. It emerges from an aberrant or
uncontrolled repair response often triggered by tissue damage
that may be initiated by radiation, mechanical injury or infections
and results in scar formation. In the context of auto-immunity,
with sustained immune activation, the injury and repair phases
persist and lead to scar tissue formation that disrupts organ archi-
tecture and function with a frequently fatal outcome (Figure 1).
In the last decade, the scientific community has successfully
collaborated through consortia to unravel the genetic basis of sus-
ceptibility for many diseases. Genome-Wide Association Studies
(GWAS) have identified numerous genetic polymorphisms that
confer higher risk for diseases and have provided insights into
the biological processes that contribute to disease susceptibility.
One key finding is the substantial overlap of genetic loci associ-
ated with disease risk across a variety of complex immune diseases
(Cotsapas and Hafler, 2013). This highlights the complexity of
the etiology of clinical phenotypes that have an immune basis
but are also largely influenced by environmental factors and can
affect different target organs. Although the target organs may
be different, a common complication of these diverse immune-
mediated diseases is the abundance of fibrotic processes and scar
tissue formation. This likely reflects that, when altered, many pro-
cesses such as inflammation, barrier function and metabolism
may result in sustained tissue injury, impaired repair processes
and ultimately fibrosis (Figure 2).
Earlier genetic studies focused on signals that distinguish
between disease and healthy status using “case-control” studies.
Recent efforts have sought to identify genetic factors influenc-
ing clinical outcomes with emerging “case-case” studies, looking
at patient subgroups that follow different disease courses. The
hope is this will provide insights into the pathogenic processes
dictating disease progression and severity. Emerging results on
genetic disease-modifiers show limited overlap with genetic loci
involved in disease risk, highlighting the point that disease ini-
tiation and disease progression are not necessarily driven by
the same mechanisms. Interestingly, these studies also allow us
to determine how genetics might contribute to milder clinical
outcomes, as illustrated by the recent discovery of a common
polymorphism in FOXO3 locus affecting the TGF-β pathway
which appears associated with improved prognosis in Crohn’s
disease and rheumatoid arthritis (Lee et al., 2013a). Further inves-
tigations will define whether, across diseases involving different
organ systems, genetic variants affecting a set of common key
biological pathways might favor more susceptibility to fibrotic
complications.
DISEASES ASSOCIATED WITH LUNG FIBROSIS
IDIOPATHIC INTERSTITIAL PNEUMONIAS AND IDIOPATHIC
PULMONARY FIBROSIS
Familial forms of idiopathic pulmonary fibrosis (IPF) account
for 2–20% of IPF patients, supporting a strong genetic compo-
nent in the development of the disease [reviewed in Kropski et al.
(2013)]. Investigations on families have identified genetic variants
in SFTPC (encoding surfactant protein C), SFTPA2 (encoding
surfactant protein A2),MUC5B (encoding a mucin constituent of
the mucus), as well as TERT and TERC (encoding components of
the telomerase complex) to be associated with pulmonary fibro-
sis (Nogee et al., 2001; Thomas et al., 2002; Armanios et al.,
2007; Tsakiri et al., 2007; Wang et al., 2009; van Moorsel et al.,
2010; Ono et al., 2011; Seibold et al., 2011). The genetic asso-
ciation of genetic polymorphisms in MUC5B-MUC2-TOLLIP as
well as TERT and TERC loci with high risk for pulmonary fibro-
sis has been confirmed by recent results from GWAS comparing
4683 controls and 1616 cases of fibrotic idiopathic interstitial
pneumonias (IIP) including 77% of IPF cases with independent
replication cohort (Fingerlin et al., 2013). These observations
provide justification for investigating familial diseases with link-
age studies, as well as large GWAS approaches.
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The implication of genetic polymorphisms in SFTPA2, SFTPC,
MUC5B as well as DSP (encoding desmoplakin) as risk factors
for pulmonary fibrosis suggest that the integrity of the barrier
function is critically important in maintaining lung homeosta-
sis (Fingerlin et al., 2013). Coding mutations in SFTPC associated
with pulmonary fibrosis lead to aberrant pro-surfactant protein
C intermediate products which cause alterations in protein mat-
uration [reviewed in Tanjore et al. (2013), Thurm et al. (2013)].
These mutations are often, but not always, detected in conjunc-
tion with activation of the Unfolded Protein Response (UPR)
pathway, which has also been reported in the alveolar epithelial
cells of IPF patients carrying the SFTPC L188Qmutation (Tanjore
et al., 2012; Thurm et al., 2013). SFTPA2mutations induce reten-
tion of surfactant protein A in the endoplasmic reticulum and
similarly lead to UPR activation (Wang et al., 2009; Maitra et al.,
2010). Two proposed mechanisms link UPR activation to tissue
injury and fibrosis: UPR activation likely increases the loss of
epithelial cells after injury and may also be involved in promoting
epithelial-to-mesenchymal (EMT) transition (Tanjore et al., 2011;
FIGURE 1 | Effect of pulmonary fibrosis on lung architecture. The
architecture of the lung in idiopathic pulmonary fibrosis (IPF) is characterized
by a so-called “honeycomb” pattern with airways separated by bands of
inflamed fibrous connective tissue and to a lesser extent, smooth muscle.
The modifications of the lung architecture induced by the fibrosis lead to
compromised diffusion of oxygen and carbon dioxide and impaired
pulmonary function. Hematoxylin and eosin staining of human normal lung
and IPF lung (scale bar = 100um). Courtesy of Dr. Robert Dunstan.
Zhong et al., 2011). Both these mechanisms likely favor the cycle
of aberrant injury and repair that is typical of fibrotic responses.
Recent studies have, however, also revealed that SFTPA1 and
SFTPCmutations induce excessive TGF-β secretion (Maitra et al.,
2012, 2013). Depending on the mutations, this effect does not
always depend on UPR activation. This brings into question the
importance of the role of UPR activation in promoting profi-
brotic phenotype associated with the polymorphisms identified
by genetic studies.
The rs35705950 risk Single Nucleotide Polymorphism (SNP)
for pulmonary fibrosis in the MUC5B region has generated a lot
of interest. MUC5B expression is reported to be higher in the lung
of IPF vs. healthy subjects, and in subjects carrying rs35705950
risk allele (Seibold et al., 2011).MUC5B encodes a member of the
mucin family, which contains highly glycosylated proteins that are
component of mucus secretions that protect the epithelial layer.
Perhaps unexpectedly, rs35705950 was recently associated with
improved survival in an IPF (Peljto et al., 2013). This supports
the concept that underlying mechanisms of disease initiation and
disease progression may be quite distinct. Given these recent rev-
elations, it has now been proposed that the increased expression
of MUC5B predisposes to IPF, but probably also has a beneficial
role in enhancing the mucosal host defense during tissue damage.
Additional SNPs in the MUC5B region including in the TOLLIP
and MUC2 loci are also associated with higher risk for IPF and
the biological contribution of these SNPs in the increased risk for
IPF remains to be elucidated (Fingerlin et al., 2013).
AsMUC5B, SFTPC, and SFTPA1 are expressed by alveolar type
II cells, this raises the possibility that injury of these cells is a crit-
ical pathogenic mechanism in pulmonary fibrosis (Seibold et al.,
2013). This hypothesis is supported by the observation that lung
fibrosis occurs following ablation of alveolar type II in genetically
modified mice using diphtheria toxin (DT) receptor transgene
under the control of Sftpc promoter (Sisson et al., 2010). However,
lung fibrosis was not observed in a different genetic mouse model
where the DT expression is controlled by an inducible Cre recom-
binase knocked into the Sftpc locus (Barkauskas et al., 2013).
This discrepancy in phenotype could reflect different levels of
FIGURE 2 | Selected genes located in genetic risk loci associated with
higher susceptibility for diseases with fibrotic complications. Genetic
studies have successfully identified numerous genetic risk loci associated
with higher susceptibility for diseases associated with fibrosis. Left panel
displays diseases associated with a strong immune component and the
genetic risk loci implicated in at least three of these diseases. Right panel
displays diseases associated with risk loci implicating genes involved in
non-immune function, such as barrier and metabolic functions.
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cell ablation between the two systems or the differential contri-
bution of additional lung cell populations that mediate the lung
epithelium repair.
Different studies in human and mouse models have attempted
to provide biological insights into the association of TERT and
TERC polymorphisms with pulmonary fibrosis. Several reports
showed shortened telomeres in IIP patients with or without
mutation in genes encoding components of the telomerase com-
plex, however, this was not replicated in a recent investigation
of an IPF Mexican cohort (Alder et al., 2008; Cronkhite et al.,
2008; Diaz de Leon et al., 2010; Liu et al., 2013a). In mouse
models, two independent groups reported that Tert and Terc KO
mice do not present spontaneous lung fibrosis and that Terc defi-
ciency does not affect bleomycin-induced lung fibrosis (Liu et al.,
2007; Degryse et al., 2012; Liu et al., 2013a). Degryse et al. did
not observe any phenotype on bleomycin-induced lung fibrosis
using Tert deficient mice, while Liu et al. reports a protective
effect using similar disease model but a different Tert deficient
strain. The reason of the discrepancy of these results is yet to be
elucidated. However, the protection phenotype observed in Tert
deficient mice in the bleomycin-induced lung fibrosis was simi-
lar with mice from 2nd and 4th generation despite shortening of
the telomeres. This led the authors to speculate that this effect
may not be dependent on telomere length (Liu et al., 2013a).
Supporting the notion that TERT and TERC deficiency might
contribute to pulmonary fibrosis by mechanisms dependent on
telomerase activity but not necessarily telomere length, telom-
erase activity is induced in IPF and NSIP fibroblasts and systemic
sclerosis lung compared to healthy donor samples (Fridlender
et al., 2007; Liu et al., 2013a). Furthermore, telomerase activ-
ity was recently shown to regulate Wnt signaling, mitochondrial
function and oxidative stress (Park et al., 2009; Sahin et al., 2011).
These pathways are known to be activated in human and mouse
disease tissues and the inhibition of Wnt/beta catenin pathways
and oxidative stress decreases fibrosis in mouse models and are
therefore currently considered as attractive therapeutic fibrosis
targets (Lam and Gottardi, 2011; Hecker et al., 2012).
The examples described above show genetic studies have suc-
cessfully unraveled key components of the genetic architecture of
IIP and IPF by leveraging the strong genetic signals associated
with disease in familial cases. Functional in-vivo characterizations
of the genetic polymorphisms associated with pulmonary fibrosis
are now starting to provide insights into potential mechanisms
that remain to be further validated. Emerging efforts to evaluate
the role of the susceptibility loci for pulmonary fibrosis have led
to unexpected results, as demonstrated by the discovery of the
association of MUC5B variant with disease risk, but improved
disease prognosis. Additional genetic polymorphisms are pro-
posed to affect IPF severity, such as TLR3 L412F, and FcγRIIa
R131H variants, which further reflect the influence of immune
mechanisms in IPF progression (Bournazos et al., 2010; O’Dwyer
et al., 2013). Polymorphisms in the angiotensinogen promoter
are also described to be associated with further decline of pul-
monary function in IPF subjects perhaps consistent with results
from mouse models in which the angiotensin pathway promotes
fibrosis (Molina-Molina et al., 2008; Dang et al., 2013). However,
these results are yet to be replicated in well-powered studies.
These examples clearly demonstrate the need for genetic studies
of disease progression to further understand pathogenesis, along-
side development of mouse models and in-vitro/ex-vivo models
of human, cells and tissues to fully validate the leads provided by
genetic studies.
INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
Systemic Sclerosis (SSc) is thought to be a chronic systemic
autoimmune disease with limited genetic component because
of the rare familial cases and low concordance for disease
in monozygotic twins (4.7%) (Feghali-Bostwick et al., 2003).
However, the concordance in monozygotic twins for the pres-
ence of antinuclear antibodies in SSc is very high (90 vs. 40%
for dizygotic twins), suggesting that the auto-immunity compo-
nent of SSc is highly inheritable, but that the disease phenotype
may be influenced by other factors that are largely not dependent
on genetics. Despite limited disease heritability, several GWAS
have detected genetic associations with risk for SSc and appear
to have confirmed the role of the immune response in the disease
risk. Many of the identified risk loci are shared with Rheumatoid
Arthritis and Systemic Lupus Erythematous, including alleles
located in MHC, STAT4, CD247, and IRF5 loci (Radstake et al.,
2010; Allanore et al., 2011; Gorlova et al., 2011). These genes sug-
gest that dysregulation of different components of the immune
response influence auto-immunity. For example, STAT4 regulates
signaling from IL-12 and IL-23 receptors in T-cells and from IFN
receptor in monocytes and NK cells, while IRF5 is a transcription
factor in the type 1 interferon pathway, and CD247 encodes for
a subunit of the T-cell receptor and modulates T-cell activation
[reviewed in Romano et al. (2011)]. However, precise functional
consequences of the risk alleles discovered in these loci still remain
to be elucidated. These studies come with great challenges for
ex-vivo studies using samples from patients carrying risk and
non-risk alleles, and with the development of mouse models with
knock-in of risk alleles for in-vivo studies.
Interstitial lung disease (ILD) is one complication of SSc and is
most often associated with diffuse cutaneous disease and the pres-
ence of anti-topoisomerase I antibodies (Steen et al., 1988; Assassi
et al., 2010). Genetic candidate approach studies (albeit with lim-
ited sample size) have identified genetic polymorphisms associ-
ated with SSc-ILD in CTGF,HGF,MMP12, which encode known
regulators of fibrotic responses, and in IRAK1 and NLRP1, which
encode proteins involved innate immune responses (Fonseca
et al., 2007; Manetti et al., 2010; Dieudé et al., 2011a,b; Hoshino
et al., 2011; Sharif et al., 2012) (see Table 1). Similar to the above
example where the MUC5B rs35705950 SNP is associated with
IPF susceptibility but with improved prognosis, the IRF5 SNP
rs4728142 confers higher risk for SSc, but also longer survival
with milder ILD (Sharif et al., 2012). Combination of the risk
alleles at STAT4 SNP rs7574865 and IRF5 SNP rs2004640 leads
to increased risk for ILD, highlighting that studies of genetic
interactions may be relevant for disease (Dieudé et al., 2009).
Observations such as this reflect the complexity of these diseases.
While IPF and SSc-ILD present with distinct clinical features,
they are both characterized by the presence of fibrotic lesions in
the lung at end stage disease. Similar gene expression profiles are
detected in lung explants from IPF and SSc patients, suggesting
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Table 1 | Genetic polymorphisms proposed to be associated with SSc-ILD.
Association with phenotypes
Variants Genes Population Discovery Replication Replication Odd ratio p = value Anti-
SLC70
SSc Expression Ref
rs2276109 MMP12 Italian 250/263 2.94 (95% CI
1.25–6.95)
p = 0.01 Yes ILD higher level
of MMP12
Manetti et al.,
2010
CTGF
-945GG
CTGF UK 200/188 300/312 3.1 (95% CI,
1.9–5.0)
p < 0.001 Yes ILD higher level
of CTGF
Fonseca et al.,
2007
HGF -1652
TT
HGF Japanese 159/103 155/0 8.1 (95% CI
2.5–26.0)
p = 0.0004 NA ESLD lower level
of HGF
Hoshino et al.,
2011
rs1059702 IRAK1 EU 849/625 495/509 466/1083 2.09 (95% CI
1.35–3.24)
p = 0.0009 Yes ILD Dieudé et al.,
2011a, 2009
rs8182352 NLRP1 EU 870/962 532/324 527/301 1.19 (95% CI
1.05–1.36)
p = 0.0065 Yes ILD Dieudé et al.,
2011b
rs2004640
rs7574865
IRF5
STAT4
French ## 179/374 ## 134/374 1.786 (95% Cl
1.25–2.58)
p = 0.002 NA ILD Dieudé et al.,
2009
VARIANTS ASSOCIATED WITH IMPROVED PROGNOSIS
rs4728142 IRF5 Caucasian 914 cases 529 cases 0.75 (95% CI
0.62–0.90)
p = 0.002 Longer
survival
Lower level
of IRF5
Sharif et al.,
2012
Candidate gene approach studies with limited power but increasing sample sizes have reported several candidate polymorphisms that may confer risk for SSc-ILD.
Discovery and Replication stages show numbers of case and control patients. ## symbol indicate a case-case study.
some overlap in pathogenicmechanisms (Hsu et al., 2011;Murray
et al., 2012). This hypothesis was tested with three independent
studies that investigated the MUC5B SNP rs35705950 risk allele
for IPF in SSc-ILD. There was no association with SSc-ILD, while
the association with IPF was confirmed by all groups (Peljto
et al., 2012; Borie et al., 2013; Stock et al., 2013). This result
further highlights the differences in pathogenic mechanisms asso-
ciated with IPF and SSc-ILD, even when the disease tissue gene
expression profiles may be similar.
Understanding the genetic architecture associated with
SSc-ILD will be crucial to provide biological insights into
the pathogenic mechanisms driving this debilitating disease.
Breakthrough discoveries will require well-powered studies and
comprehensive genetic analysis with meta-analysis of genome-
wide data rather than candidate gene studies.
DISEASES ASSOCIATED WITH RENAL FIBROSIS
Tubulointerstitial fibrosis is a feature of progression of chronic
kidney diseases (CKD) and diabetic nephropathy (DN). The inci-
dence of end stage renal disease in African Americans is known
to be 3–4-fold higher compared to non-African Americans (Li
et al., 2004). This excess risk is thought to be mainly due to
genetic polymorphisms in the MY9H/APOL1 region with a non-
synonymous SNP in APOL1 locus (Kao et al., 2008; Kopp et al.,
2008). Interestingly, this polymorphism appears to result from
a positive selection in population of African ancestry, due to
a functional advantage over sleeping sickness (Genovese et al.,
2010).
CHRONIC KIDNEY DISEASE
GWAS have identified genetic polymorphisms associated with
renal function and susceptibility to CKD. Genetic polymorphisms
inUMOD, SOX11, and PRKAG2 loci appear associated with CKD
(Köttgen et al., 2009, 2010; Gudbjartsson et al., 2010). Mutations
in UMOD are linked to familial kidney diseases, and common
polymorphisms in the UMOD locus were shown to be associ-
ated with risk for CKD in two GWAS scans (Köttgen et al., 2009,
2010; Vyletal et al., 2010). UMOD encodes uromodulin, which
is released in the urine and plays a protective role against uri-
nary tract infections and ischemia-induced acute kidney injury,
as shown in studies of Umod-deficient animals (Bates et al., 2004;
Mo et al., 2004; El-Achkar et al., 2008). The underlying mech-
anisms are unclear as uromodulin appears to have cell-specific
effects that could be both pro-inflammatory (on macrophages
and neutrophils) or anti-inflammatory [reviewed in El-Achkar
and Wu (2012)].
SOX11 appears essential for embryonic development as Sox11-
deficient mice die at birth with many malformations (Hargrave
et al., 1997; Sock et al., 2004). Sox11 was shown to control the
expression of Wnt4 in Xenopus (Murugan et al., 2012). Wnt4
signaling is known to play a key role in nephrogenesis, as its acti-
vation promotes renal fibrosis in mouse models (Kispert et al.,
1998; Surendran et al., 2002). In addition, missense mutations in
WNT4 locus are associated with renal hypodysplasia in humans
(Vivante et al., 2013). Thus, onemay speculate that SOX11 genetic
variants associated with CKDmight affect renal function through
dysregulation of Wnt4 pathway; this hypothesis remains to be
tested.
PRKAG2 encodes a subunit of the energy sensor AMP-
activated protein kinase (AMPK) whose role in renal homeosta-
sis has been extensively studied (Hallows et al., 2010). In the
context of tissue injury, activation of AMPK inhibits Epithelial-
to-Mesenchymal Transition EMT and Reactive Oxygen Species
(ROS) production induced by known pro-fibrotic factors in renal
fibrosis, such as TGF-β, angiotensin II and high glucose (Lee et al.,
2013b). It is also reported to promote Monocyte-to-Fibroblast
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transition (Yang et al., 2013). AMPK activity was shown to be pro-
tective in non-diabetic and in high fat diet-induced renal disease
models (Declèves et al., 2011; Satriano et al., 2013). The beneficial
effects of metformin, an AMPK activator, on renal function are
recognized, but its use in CKD is currently at the center of contro-
versial debates due to potential risk of lactic acidosis in the context
of renal deficiency, (Ekström et al., 2012; Rocha et al., 2013).
DIABETIC NEPHROPATHY
DN is a common complication of type 1 and type 2 dia-
betes, which have been associated with very distinct disease risk
loci [Figure 2 and reviewed in Ntzani and Kavvoura (2012),
Polychronakos and Li (2011)]. Results of genetics studies are
extensively discussed in two recent reviews (Gu and Brismar,
2012; Palmer and Freedman, 2012), we therefore will focus only
on the genetic association of ELMO1, CNDP1, and FRDM3 loci
with DN risk, as they were detected in both GWAS and candidate
gene approach studies.
ELMO1 encodes Engulfment and cell motility 1 and regulates
Rac signaling and biological processes linked actin cytoskeleton
remodeling. ELMO1 plays an established role in the clearance of
apoptotic cells (Park et al., 2007; Elliott et al., 2010; vanHam et al.,
2012), leading to the hypothesis that ELMO1 regulates homeosta-
sis upon kidney injury by ensuring clearance of apoptotic cells
and that impairment of this functionmight promote DN. ELMO1
is also known to contribute to the development of vasculature and
to the production of extracellular matrix protein (ECM), which
both may affect renal fibrosis (Shimazaki et al., 2006; Epting et al.,
2010).
CNDP1 encodes carnosinase that hydrolyzes carnosine, an
anti-oxidant molecule. Carnosine is a protective factor in several
animal models of renal disease and was shown to inhibit TGF-β
and ECM production by mesangial cells in hyperglycemic condi-
tions (Köppel et al., 2011; Riedl et al., 2011; Menini et al., 2012).
While CNDP1 polymorphisms are suspected to affect the level of
its substrate carnosine, this remains to be demonstrated.
Little is known about the biological function of FRDM3, how-
ever, its locus is proposed to be associated with defective renal
function in rats, based onQuantitative Trait Loci analysis (Garrett
et al., 2010). It was recently suggested that FRDM3 risk SNP for
DN may affect BMP signaling, a hypothesis that remains to be
validated (Martini et al., 2013).
Genetic studies have identified many genetic polymorphisms
that confer risk for CKD and DN using the gene candidate
approach, but GWAS often have not confirmed these associations
(Gu and Brismar, 2012; Palmer and Freedman, 2012). Current
studies include only cross-sectional measurements of renal func-
tion, and genetic factors affecting disease progression of renal
diseases are yet to be elucidated.
DISEASES ASSOCIATED WITH LIVER FIBROSIS
AUTOIMMUNE LIVER DISEASES
The genetic architecture of autoimminue liver diseases such
as Primary Sclerosing Cholangitis (PSC) and Primary Biliary
Cirrhosis (PBC) was recently studied through a series of GWAS
(Hirschfield et al., 2009; Liu et al., 2010; Mells et al., 2011; Melum
et al., 2011; Liu et al., 2013a,b). Inflammation and tissue damage
is thought to trigger sustained aberrant tissue repair responses
that ultimately lead to the replacement of the organ by scar
fibrotic tissue. Susceptibility loci largely overlap with the loci
detected in other complex immune diseases affecting different
organs: PSC and PBC shared common risk loci withmultiple scle-
rosis, celiac disease, inflammatory bowel disease (IBD), rheuma-
toid arthritis and type 1 diabetes (Mells et al., 2013). Concurrent
autoimmune disorders are commonly present in PSC and PBC
patients (PSC is often seen in patients with IBD, type 1 diabetes
and autoimmune thyroid disease and PBC is often seen in patients
with Sjogren’s syndrome, Raynaud Phenomenon, autoimmune
thyroid disease and rheumatoid arthritis (Mells et al., 2013),
which may explain the result of the genetic studies. Due to this
co-occurrence of auto-immune diseases, case-case studies focus-
ing on disease progression will be especially critical in PBC and
PSC in order to identify pathogenic mechanisms that could be
targeted by therapies.
NON-ALCOHOLIC FATTY LIVER DISEASE
Non-Alcoholic Fatty Liver Disease (NAFLD) is strongly associ-
ated with obesity, type 2 diabetes and dyslipidemia. The disease
is characterized by steatosis with an increased hepatic Free Fatty
Acid flux and cellular damage that trigger inflammatory and
fibrotic responses. Genetic polymorphisms in the PNPLA3 locus
that encodes for adiponutrin have been associated with NAFLD
in many genetics studies using the candidate approach, and with
well-powered GWAS (Daly et al., 2011). Adiponutrin is a triacyl-
glycerol hydrolase, and the I148M variant associated with NAFLD
induces accumulation of triacylglycerol and hepatic steatosis (He
et al., 2010; Li et al., 2012). In independent studies, PNPLA3 locus
has also been associated with NAFLD progression and fibrosis
(Speliotes et al., 2011; Kitamoto et al., 2013). Additional poten-
tial genetic disease-modifiers associated with fibrosis reported
in these studies are NCAN, GCKR, LYPLAL1, SAMM50, and
PARVB loci. LYLPAL1 encodes a lysophospholipase and GCKR
encodes glucokinase regulatory protein that regulates both glu-
cose metabolism and lipogenesis. GCKR and NCAN variants
affect circulating triglyceride levels (Gorden et al., 2013; Shen
et al., 2013). Altogether, this suggests that risk for NAFLD and
its progression could be largely influenced by genetic factors
regulating lipid metabolism.
Genetic variants of angiotensin II receptor 1 have also been
reported to be linked to fibrosis in NAFLD in two different
studies, but with some inconsistencies in effects of AGTR1 vari-
ants/alleles perhaps due to cohort ethnicities (Yoneda et al., 2009;
Zain et al., 2013). The use of blockers of angiotensin recep-
tor in patients with liver fibrosis has yielded different results,
therefore their beneficial effect in NAFLD remains controversial
(Yokohama et al., 2004; Abu Dayyeh et al., 2011; Hirata et al.,
2013). Thus, understanding the role of ATGR1 genetic polymor-
phisms in the progression of NAFLD liver fibrosis, and defining
the relevant patient population, might be crucial to evaluate
the potential beneficial role of angiotensin receptor blockers in
NAFLD progression.
DISEASES ASSOCIATED WITH INTESTINAL FIBROSIS
Intestinal fibrosis is a common complication occurring with
intestinal inflammation such as that seen with IBD, which
comprises both Crohn’s Disease (CD) and Ulcerative Colitis (UC)
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(Speca et al., 2012). The GWAS approach was very successful
in identifying more than a hundred genetic risk factors for IBD
(Franke et al., 2010; Anderson et al., 2011). These discoveries
highlighted a major role for inflammatory pathways controlling
innate and adaptive immune responses, mucosal barrier func-
tion, endoplasmic reticulum stress and oxidative stress in the
disease pathogenesis (Khor et al., 2011). The chronic inflam-
matory injury in IBD triggers unrelenting mucosal injury/repair
processes, and this ongoing damage/repair cycle is thought to
underlie the intestinal fibrosis and strictures that are commonly
seen in CD patients. In a subset of CD patients, the fibrosis and
strictures can lead to intestinal obstruction and thus surgery.
Immunosuppressive and anti-inflammatory treatments have little
effects on intestinal fibrosis once the process has started, sug-
gesting that non-immune pathways must be playing a role in the
progression of fibrosis.
It is somehow surprising that there are only a few reports on
genetic polymorphisms associated with higher risk for intesti-
nal fibrosis, despite the strong success in recruiting a large
number of patients for the IBD GWAS efforts. Candidate-gene
approach studies with small size cohorts have implicated NOD2
and CX3CR1 polymorphisms as higher risk factors for strictur-
ing CD and the subsequent need for surgery (Abreu et al., 2002;
Lesage et al., 2002; Brand et al., 2006; Seiderer et al., 2006; Sabate
et al., 2008).NOD2 is a known risk factor for CD and is presumed
to primarily control innate immune response to bacterial prod-
ucts, whileCX3CR1 is a chemokine receptor involved in leukocyte
recruitment. In addition, GWAS to identify genetic polymor-
phisms associated with CD severity has recently implicated several
loci including IL12B, RXRA/COL5A1, AHR, and FOXO3 loci in
severe clinical phenotypes defined by need for surgery (Dubinsky
et al., 2013; Lee et al., 2013b). However, their specific association
to structuring CD is unclear. It is the hope that future studies will
able to identify genetic risk factors associated with the structuring
CD to better understand the pathogenesis of the development of
intestinal fibrosis in IBD.
DISEASES ASSOCIATED WITH SKIN FIBROSIS
Skin fibrosis represents a cardinal feature of several diseases
with debilitating skin pathologies, including keloid dis-
ease/hypertrophic scars, systemic sclerosis and nephrogenic
systemic fibrosis. While the etiology of skin fibrosis remains
poorly understood, growing evidence supports the hypothesis
that fibrosis arises from aberrant tissue injury (e.g., vasculopathy)
and repair (e.g., wound healing) responses.
A number of studies in recent years have investigated the
genetic basis of skin fibrosis, especially in keloid disease (KD)
where higher prevalence in ethnicities with darker pigmenta-
tion. Linkage studies in familial keloids have been reported,
with suggested candidate genes involved in fibroblast prolifer-
ation (EGFR), inflammation (TNFAIP6), and TGF-β signaling
(SMADs) (Marneros et al., 2004; Yan et al., 2007). Supporting
the potential role of inflammation and/or immune activation in
the pathogenesis of KD, polymorphisms in the HLA region are
associated with increased risk for KD in Caucasian, Chinese and
Black populations (Brown et al., 2008, 2010; Lu et al., 2008). More
recently, two independent GWAS of KD in Japanese and Chinese
populations identified risk SNPs in chromosomal regions 1q41
and 15q21.3 (NEDD4 locus) (Nakashima et al., 2010; Zhu et al.,
2013). It will be of great interest to understand how these loci
may confer disease susceptibility for KD whose etiology is poorly
understood.
Several candidate gene and GWAS have been carried out in
systemic sclerosis (SSc), with most of the genetic variants iden-
tified being immune regulatory genes as mentioned earlier in
this review. While these findings clearly support a major role of
autoimmunity in SSc genetics, it is less clear whether these SSc
susceptibility loci are directly involved in SSc skin fibrosis. SSc can
be divided in two subtypes and the extent of the skin fibrosis is
greater in diffuse SSc than in limited SSc. GWAS in SSc detected
only one locus in ZC3H10/ESYT1 region conferring susceptibil-
ity preferentially for the diffuse clinical phenotype (Gorlova et al.,
2011). It remains to be elucidated whether there is relationship
between this risk locus and any pathogenic mechanisms linked
to the skin fibrosis in diffuse SSc. Since 90% of the SSc patients
have Raynaud’s syndrome preceding their onset of skin harden-
ing by several years, and vasculopathy is often viewed that may
be a key disease-driving cause of SSc, it is somewhat surprising
that no vasculature-related genes have been described from the
SSc GWAS studies so far.
In addition to risk factors for SSc, an allele in CAV1 locus
(encoding caveolin 1) was recently shown in a French cohort and
replicated in an Italian cohort to confer protection against SSc
and in particular limited SSc (Manetti et al., 2012). This protec-
tive allele was shown to be associated with an increased expression
of caveolin 1 in skin from both healthy subjects and SSc patients.
Caveolin 1 is a component of membrane caveolae that is pro-
posed to regulate TGF-β receptor degradation (Del Galdo et al.,
2008a). Confirming an anti-fibrotic role of caveolin 1, Cav1-
deficient mice develop spontaneous lung and skin fibrosis (Drab
et al., 2001; Del Galdo et al., 2008a,b). Caveolin 1 expression is
decreased in many human fibrosis tissues including SSc skin and
lung, IPF lung and keloid-derived fibroblasts, which suggest that
the caveolin 1-mediated regulatory pathway may represent a new
therapeutic opportunity in fibrotic diseases (Wang et al., 2006;
Del Galdo et al., 2008a,b; Zhang et al., 2011).
FIBROSIS PROGRESSION: PROMISING STUDIES IN CYSTIC
FIBROSIS AND HCV-INDUCED FIBROSIS
Cystic fibrosis arises as the result of an abnormal transport of salt
due to mutations in CTFR. Although this is a Mendelian disorder,
additional genetic factors are emerging as disease modifiers due to
their influence on disease severity. Polymorphisms in MUC5AC
may affect the severity of cystic fibrosis lung disease highlight-
ing further the role of mucin in maintaining lung homeostasis
(Guo et al., 2011). A recent GWAS meta-analysis including more
than 3000 patients detected a SNP in a large intergenic region
near EHF and APIP to be associated with disease severity (Wright
et al., 2011). Additional suggestive (close to genome-wide sig-
nificance) associations were reported in AGTR2 and in AHRR
regions, indicating a role for angiotensin and xenobiotic sensing
pathways in the severity of cystic fibrosis. As mentioned previ-
ously, the angiotensin pathwaymay be involved in the progression
of NAFLD. Strikingly, angiotensin receptor blockade protects
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FIGURE 3 | Overview of biological processes and pathways proposed to
be associated with disease risk and disease progression. Left panel
shows the biological processes associated with the genes located in the risk
loci associated with higher susceptibility for disease. Right panel shows the
biological pathways associated with genes located in the loci associated with
disease progression. Further genetic studies of disease progression are
needed to confirm initial results from limited sample sizes. SSc,
systemic#sclerosis; PSC, primary sclerosing cholangitis; PBC, primary biliary
cirrhosis; T1D, type 1 diabetes; T2D, type 2 diabetes; IBD, inflammatory
bowel disease; IIP, idiopathic interstitial pneumonias; CKD, chronic kidney
disease; NAFLD, non-alcoholic fatty liver disease; ILD, interstitial lung
disease; IPF, idiopathic pulmonary fibrosis.
from experimental lung fibrosis and Ahr-deficient mice develop
hepatic fibrosis (Fernandez-Salguero et al., 1995; Andreola et al.,
2004; Waseda et al., 2008; Yaguchi et al., 2013). Further studies
will be required to test the hypothesis that these pathways may
be critical in influencing disease progression in cystic fibrosis and
may lead to additional therapeutic approach for this Mendelian
disorder.
Genetic disease-modifiers in HCV-induced fibrosis were
recently identified in a GWAS meta-analysis including more than
2000 patients (Patin et al., 2012). Genetic polymorphisms in
RNF7 and MERTK were associated with fibrosis progression and
also point to the previously mentioned involvement of oxida-
tive stress and the clearance of apoptotic cells in fibrotic diseases
(Duan et al., 1999; Scott et al., 2001; Zizzo et al., 2012). Different
candidate gene approach studies detected rs12785878 near
DHCR7 to be associated with 25-hydroxyvitamin D [25(OH)D]
serum levels, liver stiffness in chronic liver diseases, and progres-
sion of liver fibrosis in HCV patients (Grünhage et al., 2012; Petta
et al., 2013). The same SNP was associated with development of
hepatocarcinoma, but not with progression rate of liver fibrosis
in HCV patients (Lange et al., 2013). Strikingly, vitamin D recep-
tor was demonstrated to be key in the control of liver fibrosis
by affecting SMAD3-mediated transcriptional response in mouse
model, supporting the notion that this pathwaymight be essential
in the control of liver fibrosis (Ding et al., 2013).
Together these studies confirm that genetics may play a critical
role in influencing disease progression independently of the cause
of the fibrosis (Mendelian or infectious disease). Understanding
the underlying biological pathways associated with these disease
modifiers, and how they influence fibrosis, may lead to new leads
for therapeutic strategies.
CONCLUDING REMARKS
Genetic studies have successfully identified polymorphisms asso-
ciated with susceptibility for diseases with fibrotic complications.
On-going functional studies attempt to elucidate the underly-
ing pathogenic mechanisms. After a decade of human genetics
studies focusing on disease risk, emerging results from genetic
studies of disease progression suggest a multi-hit paradigm in
which disease initiation and disease progression are not necessar-
ily driven by the same mechanisms (Figure 3). Early discoveries
on fibrosis progression point to pathways already shown inmouse
models to control fibrotic responses, such as vitamin D and xeno-
biotic sensing pathways. Perhaps future genetic studies on disease
progression will identify more genes and pathways identified in
mouse models to control fibrotic responses.
The identification of genetic disease modifiers comes with
great challenges with a requirement for clinical annotations to
inform on disease progression or severity with well-powered
case-case studies rather than case-control studies to understand
disease progression in human fibrotic diseases. However, eluci-
dating the genetic basis of disease severity is crucial to understand
pathogenic mechanisms and may be even more relevant to high-
light biological pathways for therapeutic interventions.
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